MetaCap

IRulya Therapeutics (IRLA) vs ProKidney (PROK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

IRulya Therapeutics is the larger company by market cap ($432.4 million vs $415.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IRLA+17.16%PROK-21.80%
+55%+15%-25%
Aug 14, 20261 yearNov 20, 2026
IRLA+17.16%PROK-21.80%
+55%+15%-25%
Aug 10, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IRLA versus PROK key metrics
MetricIRLAPROK
Share price$39.88$1.04
Market cap$432.36M$415.21M
1-day change-0.15%-1.89%
YTD return—-53.57%
1-year return—-52.51%
5-year return—-89.49%
EPS (TTM)$-162.79$-0.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$893.00K
Revenue growth (YoY)—+1075.00%
Net income (latest FY)$-83.98M$-68.99M
Operating margin—-18477.83%
Net margin—-7725.20%
52-week high$910.00$2.65
52-week low$15.10$0.87
Distance from 52-week high-95.62%-60.75%
Analyst consensusstrong_buybuy
Avg. price target upside+90.90%+525.00%
Average volume63.03K1.44M
Shares outstanding10.84M209.63M
Employees38231
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About IRulya Therapeutics

IRLA stock →

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees

About ProKidney

PROK stock →

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees

IRLA vs PROK FAQ

Which is bigger, IRulya Therapeutics or ProKidney?

IRulya Therapeutics (IRLA) is larger, with a market capitalization of $432.36M compared with $415.21M for ProKidney (PROK).

Are IRulya Therapeutics and ProKidney in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons